Cargando…
Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects
BACKGROUND: We are developing cancer immunotherapy based on the use of autologous tumor tissue that has been rendered replication-incompetent but maintains phenotype and metabolic activity post-preparation. AIM: The aim of this study was to evaluate safety and tolerance to injection of the inactivat...
Autores principales: | Goodrich, Raymond P., Weston, Jon, Hartson, Lindsay, Griffin, Lynn, Guth, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568153/ https://www.ncbi.nlm.nih.gov/pubmed/33102607 http://dx.doi.org/10.1155/2020/7142375 |
Ejemplares similares
-
Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies
por: Cardoso, Marcia, et al.
Publicado: (2023) -
Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
por: Ragan, Izabela, et al.
Publicado: (2020) -
Preservation of neutralizing antibody function in COVID‐19 convalescent plasma treated using a riboflavin and ultraviolet light‐based pathogen reduction technology
por: Yonemura, Susan, et al.
Publicado: (2021) -
Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma
por: Musser, Margaret L., et al.
Publicado: (2022) -
Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light
por: Ragan, Izabela K., et al.
Publicado: (2023)